IBDEI0GU ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,8144,0)
 ;;=364.41^^52^578^50
 ;;^UTILITY(U,$J,358.3,8144,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8144,1,3,0)
 ;;=3^Hyphema
 ;;^UTILITY(U,$J,358.3,8144,1,4,0)
 ;;=4^364.41
 ;;^UTILITY(U,$J,358.3,8144,2)
 ;;=Hyphema^60498
 ;;^UTILITY(U,$J,358.3,8145,0)
 ;;=364.05^^52^578^51
 ;;^UTILITY(U,$J,358.3,8145,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8145,1,3,0)
 ;;=3^Hypopyon
 ;;^UTILITY(U,$J,358.3,8145,1,4,0)
 ;;=4^364.05
 ;;^UTILITY(U,$J,358.3,8145,2)
 ;;=Hypopion^60720
 ;;^UTILITY(U,$J,358.3,8146,0)
 ;;=365.02^^52^578^4
 ;;^UTILITY(U,$J,358.3,8146,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8146,1,3,0)
 ;;=3^Angle, Narrow
 ;;^UTILITY(U,$J,358.3,8146,1,4,0)
 ;;=4^365.02
 ;;^UTILITY(U,$J,358.3,8146,2)
 ;;=Angle, Narrow^268748
 ;;^UTILITY(U,$J,358.3,8147,0)
 ;;=372.63^^52^578^117
 ;;^UTILITY(U,$J,358.3,8147,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8147,1,3,0)
 ;;=3^Symblepharon
 ;;^UTILITY(U,$J,358.3,8147,1,4,0)
 ;;=4^372.63
 ;;^UTILITY(U,$J,358.3,8147,2)
 ;;=Symblepharon^265885
 ;;^UTILITY(U,$J,358.3,8148,0)
 ;;=372.75^^52^578^27
 ;;^UTILITY(U,$J,358.3,8148,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8148,1,3,0)
 ;;=3^Cysts, Conjunctival
 ;;^UTILITY(U,$J,358.3,8148,1,4,0)
 ;;=4^372.75
 ;;^UTILITY(U,$J,358.3,8148,2)
 ;;=Cysts, Conjunctival^269049
 ;;^UTILITY(U,$J,358.3,8149,0)
 ;;=364.81^^52^578^43
 ;;^UTILITY(U,$J,358.3,8149,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8149,1,3,0)
 ;;=3^Floppy Iris Syndrome
 ;;^UTILITY(U,$J,358.3,8149,1,4,0)
 ;;=4^364.81
 ;;^UTILITY(U,$J,358.3,8149,2)
 ;;=^335254
 ;;^UTILITY(U,$J,358.3,8150,0)
 ;;=006.9^^52^578^2
 ;;^UTILITY(U,$J,358.3,8150,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8150,1,3,0)
 ;;=3^Amebiasis
 ;;^UTILITY(U,$J,358.3,8150,1,4,0)
 ;;=4^006.9
 ;;^UTILITY(U,$J,358.3,8150,2)
 ;;=^5818
 ;;^UTILITY(U,$J,358.3,8151,0)
 ;;=190.8^^52^578^60
 ;;^UTILITY(U,$J,358.3,8151,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8151,1,3,0)
 ;;=3^Iris Melanoma,Contiguous Site
 ;;^UTILITY(U,$J,358.3,8151,1,4,0)
 ;;=4^190.8
 ;;^UTILITY(U,$J,358.3,8151,2)
 ;;=^267278
 ;;^UTILITY(U,$J,358.3,8152,0)
 ;;=224.1^^52^578^93
 ;;^UTILITY(U,$J,358.3,8152,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8152,1,3,0)
 ;;=3^Orbit Neoplasm,Benign
 ;;^UTILITY(U,$J,358.3,8152,1,4,0)
 ;;=4^224.1
 ;;^UTILITY(U,$J,358.3,8152,2)
 ;;=^267671
 ;;^UTILITY(U,$J,358.3,8153,0)
 ;;=360.33^^52^578^52
 ;;^UTILITY(U,$J,358.3,8153,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8153,1,3,0)
 ;;=3^Hypotony,Assoc w/ Ocular D/O
 ;;^UTILITY(U,$J,358.3,8153,1,4,0)
 ;;=4^360.33
 ;;^UTILITY(U,$J,358.3,8153,2)
 ;;=^268560
 ;;^UTILITY(U,$J,358.3,8154,0)
 ;;=224.8^^52^578^86
 ;;^UTILITY(U,$J,358.3,8154,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8154,1,3,0)
 ;;=3^Neopl Eye Bgn,Oth Iris Nevus
 ;;^UTILITY(U,$J,358.3,8154,1,4,0)
 ;;=4^224.8
 ;;^UTILITY(U,$J,358.3,8154,2)
 ;;=^267678
 ;;^UTILITY(U,$J,358.3,8155,0)
 ;;=364.01^^52^578^103
 ;;^UTILITY(U,$J,358.3,8155,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8155,1,3,0)
 ;;=3^Prim Iridocyclitis
 ;;^UTILITY(U,$J,358.3,8155,1,4,0)
 ;;=4^364.01
 ;;^UTILITY(U,$J,358.3,8155,2)
 ;;=^268704
 ;;^UTILITY(U,$J,358.3,8156,0)
 ;;=364.04^^52^578^53
 ;;^UTILITY(U,$J,358.3,8156,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8156,1,3,0)
 ;;=3^Iridociclyties 2ary,Non Infectious
 ;;^UTILITY(U,$J,358.3,8156,1,4,0)
 ;;=4^364.04
 ;;^UTILITY(U,$J,358.3,8156,2)
 ;;=^268710
 ;;^UTILITY(U,$J,358.3,8157,0)
 ;;=364.21^^52^578^46
 ;;^UTILITY(U,$J,358.3,8157,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8157,1,3,0)
 ;;=3^Fuch's Hetero Cyclitis
 ;;^UTILITY(U,$J,358.3,8157,1,4,0)
 ;;=4^364.21
